| Name | Guidepoint Pharmacy #106 |
|---|---|
| Organization Name | Ci Pharmacy Services Ltd |
| Location | 20 W Main St, Crosby, Minnesota 56441 |
| Type | Pharmacy |
| Phone | (218) 546-5144 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found.
Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.
"Color pigments from tattoos do not remain locally restricted to the skin, they migrate in the body," explains BfR President, Professor Dr. Andreas Hensel.
› Verified 2 days ago
| NPI Number | 1083635270 |
| Organization Name | CI PHARMACY SERVICES LTD |
| Doing Business As | GUIDEPOINT PHARMACY |
| Type | Pharmacy |
| Address | 20 W Main St, Crosby, MN 56441 |
| Phone Number | 218-546-5144 |
News Archive
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found.
Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.
"Color pigments from tattoos do not remain locally restricted to the skin, they migrate in the body," explains BfR President, Professor Dr. Andreas Hensel.
› Verified 2 days ago
| NPI Number | 1134621824 |
| Type | Community/Retail Pharmacy |
| Address | 20 W Main St, Crosby, MN 56441 |
| Phone Number | 218-546-5144 |
News Archive
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found.
Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.
"Color pigments from tattoos do not remain locally restricted to the skin, they migrate in the body," explains BfR President, Professor Dr. Andreas Hensel.
› Verified 2 days ago
| NPI Number | 1386125821 |
| Organization Name | CI PHARMACY SERVICES, LTD |
| Doing Business As | GUIDEPOINT PHARMACY #106 LTC |
| Type | Long Term Care Pharmacy |
| Address | 20 W Main St, Crosby, MN 56441 |
| Phone Number | 218-546-5144 |
News Archive
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found.
Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.
"Color pigments from tattoos do not remain locally restricted to the skin, they migrate in the body," explains BfR President, Professor Dr. Andreas Hensel.
› Verified 2 days ago
| NPI Number | 1740839570 |
| Type | Pharmacy |
| Address | 20 W Main St, Crosby, MN 56441 |
| Phone Number | 218-546-5144 |
News Archive
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found.
Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.
"Color pigments from tattoos do not remain locally restricted to the skin, they migrate in the body," explains BfR President, Professor Dr. Andreas Hensel.
› Verified 2 days ago
| NPI Number | 1891159018 |
| Organization Name | CI PHARMACY SERVICES, LTD |
| Doing Business As | GUIDEPOINT PHARMACY #106 |
| Type | Community/Retail Pharmacy |
| Address | 20 W Main St, Crosby, MN 56441 |
| Phone Number | 218-546-5144 |
News Archive
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found.
Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.
"Color pigments from tattoos do not remain locally restricted to the skin, they migrate in the body," explains BfR President, Professor Dr. Andreas Hensel.
› Verified 2 days ago
News Archive
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found.
Researchers studied convalescent plasma from recovered coronavirus disease 2019 (COVID-19) patients, with samples collected up to 34 weeks after recovery. They found IgG antibodies gradually declined with a median half-life of about 60 days.
"Color pigments from tattoos do not remain locally restricted to the skin, they migrate in the body," explains BfR President, Professor Dr. Andreas Hensel.
› Verified 2 days ago
Guidepoint Pharmacy #106 Type: Pharmacy Location: 20 W Main St, Crosby, Minnesota 56441 Phone: (218) 546-5144 | |
Great River Eye Clinic Type: Eyewear Supplier (Equipment, not the service) Location: 1 3rd Ave Ne, Crosby, Minnesota 56441 Phone: (218) 546-5108 |